Phase 2 N=30 Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
Alopecia Areata
Primary: Percent Change From Baseline in SALT Score at Week 24 — -12.6 percent change in score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=86 Tafenoquine in Patients With Mild to Moderate COVID-19
COVID 19 Disease
Primary: Number of Patients With Clinical Recovery of COVID-19 Symptoms on Day 14 — 8; 10; 37; 31 Participants — p=0.1879
Phase 2 N=9 Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Myelofibrosis · Chronic Myelomonocytic Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 2 N=214 Treatment Shortening of MDR-TB Using Existing and New Drugs
Tuberculosis, Multidrug-Resistant
Primary: Treatment Success Rate — 60; 54 Participants
Phase 2 N=84 Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Progression Free Survival (PFS) at 9 Month — 25.1; 35 Percentage of participants
Phase 2 N=65 A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Pseudoxanthoma Elasticum
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-1211b — 8; 7; 6; 6 Participants
Phase 2 N=15 ANC-501 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline (Day 1) to Day 56 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. — -17.5 score on a scale
Phase 2 N=20 Peripheral Oxytocin and Touch
Healthy Adults
Primary: Change in Mean Pleasantness Rating of Gentle Brushing — -8.7; -14.1 score on a scale
Phase 2 N=277 A Study of JZP150 in Adults With Posttraumatic Stress Disorder
Post Traumatic Stress Disorder
Primary: Mean Change From Baseline to Week 12 in Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS-5) Total Symptom Severity Score — -17.0; -17.8; -17.6…
Phase 2 N=25 A Gene Transfer Study for Hemophilia A
Hemophilia A
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 2; 3; 9; 11 Participants
Phase 2 N=40 Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Alpha 1-Antitrypsin Deficiency
Primary: Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16 — -62.17; -85.39; -92.93; 4.64 percentage change — p=< 0.0001
Phase 2 N=34 A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
Neovascular Age-related Macular Degeneration · Macular Edema · Retinal Vein Occlusion
Primary: Percentage of Successful Task Completions — 100; 100; 100; 100 Percentage of successful task completion
Phase 2 N=144 A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
Dermatitis, Atopic · Pruritus
Primary: Daily Peak Pruritus Numerical Rating Scale (NRS) — -45.6; -55.8; -48.3; -49.9 percent change — p=0.5483
Phase 2 N=34 Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Schizophrenia
Primary: Adverse Events — 10; 13 Participants
Phase 2 N=35 A Study of Nivolumab in Selected Uterine Cancer Patients
Uterine Cancer · Endometrial Carcinoma · Carcinosarcoma
Primary: Progression-Free Survival — 64.7 percentage of patients